Physician profile
Eric Michael Janis
NPI 1780682484
$3,005.45
in general payments reported to CMS, 2019-2025
21 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $364 · 2021: $564 · 2022: $206 · 2023: $151 · 2024: $461 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $832.26 | 2020-2025 | Watchman Flx, General - Ep, General - Therapies |
| Abbott Laboratories | $559.81 | 2019-2025 | Amplatzer Talisman, Amplatzer Amulet, Triclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $414.03 | 2019-2025 | Lifevest |
| Osprey Medical INC | $263.00 | 2019 | |
| Irhythm Technologies, INC. | $155.69 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Atricure, INC. | $151.65 | 2025 | Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Biotronik INC. | $147.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $128.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $84.70 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $47.16 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.84 | 2019-2025 | Jardiance |
| Pfizer INC. | $29.47 | 2019-2025 | |
| Shockwave Medical, INC | $28.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.20 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $22.83 | 2025 | Camzyos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $20.78 | 2024 | Carto 3 |
| Novo Nordisk INC | $16.90 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $15.07 | 2019 | |
| Philips North America LLC | $14.64 | 2022 | |
| Amgen INC. | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,178,803.67 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Janis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.